ArticleCureus2025
Posterior Cortical Atrophy Masked by a Pituitary Macroadenoma: Diagnostic Challenges in the Setting of Dual Visual Pathology.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Posterior cortical atrophy (PCA) is a rare neurodegenerative syndrome characterised by progressive visuospatial and visuoperceptual dysfunction. Diagnosis is frequently delayed, particularly when coexisting visual pathology provides an alternative explanation for symptoms. A man in his sixties with a known pituitary macroadenoma and right homonymous hemianopia presented with a four-year history of insidious visual and functional decline. Prior serial perimetric assessments demonstrated progressive, inconsistent field loss not explained by stable chiasmal compression. Neurological assessment revealed prominent posterior cortical deficits, including features of both Balint and Gerstmann syndromes. MRI demonstrated parietal-predominant cortical atrophy, and fluorodeoxyglucose-18 Positron Emission Tomography (18F-FDG-PET) confirmed marked parieto-occipital hypometabolism, establishing a diagnosis of PCA. This case illustrates how established anterior visual pathway disease can delay recognition of concurrent neurodegenerative pathology. For patients with known afferent visual impairment, clinical indicators to prompt consideration of a cortical pathology and a proposed structural assessment framework are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.